Journal Mobile Options
Table of Contents
Vol. 38, No. 6, 2005
Issue release date: November–December 2005
Psychopathology 2005;38:320–326
(DOI:10.1159/000088921)

PANSS Syndromes and Quality of Life in Schizophrenia

Karow A. · Moritz S. · Lambert M. · Schoder S. · Krausz M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Results from factor analysis studies have suggested that a five-dimensional structure appears to be a better representation of the psychopathological data of the PANSS. The purpose of this study was the detailed investigation of the association of schizophrenia syndromes and single symptoms with quality of life (QOL) in acute and remitted patients. The leading hypotheses were: (1) affective symptoms, especially depression and anxiety, are mostly associated with QOL longitudinally and (2) in the acute phase, QOL is also associated with positive schizophrenia symptoms. Methods: For the present study, schizophrenia and schizophreniform patients were studied on admission, at the end of the acute phase and 6 months after hospitalization. Psychopathology was measured using the PANSS syndromes, QOL was assessed using disease-specific (SWN) and generic (MLDL, EDLQ) scales. Results: Eighty-four patients entered the study and were assessed during the acute phase taking into account their history and actual treatment. Results revealed anxiety as the most important symptom and depression as the most important syndrome associated with different areas of QOL during and after hospitalization. Also cognitive and negative symptoms were associated with different QOL domains, but both positive symptom clusters showed no substantial association with QOL. Conclusions: Results of this longitudinal study investigating psychopathology and QOL in schizophrenia provide further support for the need to consider the psychopathological state and treatment setting when measuring QOL in schizophrenia and the need for a differential analysis of schizophrenia symptoms and QOL in the acute, mid-term and long-term phase. Anxiety reduction should be a critical goal of treatment in order to prevent further QOL impairment.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR: The sickness impact profile: Conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976;6:393–415.
  2. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH: The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657–1664.
  3. Bullinger M, Hasford J: Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials 1991;12:91S–105S.

    External Resources

  4. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan EO: Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118–124.
  5. Galletly CA, Clark CR, McFarlane AC, Weber DL: Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 1997;72:161–166.
  6. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC: Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am J Psychiatry 1998;155:1196–1201.
  7. Packer S, Husted J, Cohen S, Tomlinson G: Psychopathology and quality of life in schizophrenia. J Psychiatry Neurosci 1997;22:231–234.
  8. Dickerson FB, Ringel NB, Parente F: Subjective quality of life in out-patients with schizophrenia: Clinical and utilization correlates. Acta Psychiatr Scand 1998;98:124–127.
  9. Heslegrave RJ, Awad AG, Voruganti LN: The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 1997;22:235–243.
  10. Naber D, Moritz S, Lambert M, Pajonk F, Holzbach R, Mass R, Andresen B: Improvement of schizophrenic patients; subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79–88.
  11. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P: Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 2003;108:297–303.
  12. Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV: Association of depressive symptoms with worse functioning in schizophrenia: A study in older outpatients. J Clin Psychiatry 2001;62:797–803.
  13. Holloway F, Carson J: Subjective quality of life, psychopathology, satisfaction with care and insight: An exploratory study. Int J Soc Psychiatry 1999;45:259–267.
  14. Eklund M, Backstrom M, Hansson L: Personality and self-variables: Important determinants of subjective quality of life in schizophrenia out-patients. Acta Psychiatr Scand 2003;108:134–143.
  15. Ritsner M: Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis 2003;191:287–294.
  16. Lysaker PH, Davis LW: Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition. Health Qual Life Outcomes 2004;2:15.
  17. Heinisch M, Ludwig M, Bullinger M: Psychometrische Testung der ‘Münchner Lebensqualitäts-Dimensionen-Liste (MLDL)’; in Bullinger M, Ludwig M, von Steinbüchel N (eds): Lebensqualität bei kardiovaskulären Erkrankungen. Göttingen, Hogrefe, 1991.
  18. Naber D: A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(suppl 3):133–138.
  19. Karow A, Naber D: Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3–10.
  20. Bullinger M: Generic quality of life assessment in psychiatry. Potentials and limitations. Eur Psychiatry 1997;12:203–209.

    External Resources

  21. Fitzgerald PB, de Castella AR, Filia K, Collins J, Brewer K, Williams CL, Davey P, Kulkarni J: A longitudinal study of patient- and observer-rated quality of life in schizophrenia. Psychiatry Res 2003;119:55–62.
  22. Lasalvia A, Ruggeri M, Santolini N: Subjective quality of life: Its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6. Psychother Psychosom 2002;71:275–284.
  23. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP: Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res 1994;52:295–303.
  24. Huppert JD, Smith TE: Longitudinal analysis of subjective quality of life in schizophrenia: Anxiety as the best symptom predictor. J Nerv Ment Dis 2001;189:669–675.
  25. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE: Quality of life in schizophrenia: Contributions of anxiety and depression. Schizophr Res 2001;51:171–180.
  26. Orsel S, Akdemir A, Dag I: The sensitivity of quality-of-life scale WHOQOL-100 to psychopathological measures in schizophrenia. Compr Psychiatry 2004;45:57–61.
  27. Wetherell JL, Palmer BW, Thorp SR, Patterson TL, Golshan S, Jeste DV: Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2003;64:1476–1482.
  28. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW: Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65:932–939.
  29. Bow-Thomas CC, Velligan DI, Miller AL, Olsen J: Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res 1999;86:131–142.
  30. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
  31. DeHaan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L, Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P: Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002;162:24–28.
  32. Franz M, Lis S, Pluddemann K, Gallhofer B: Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422–425.
  33. Bullinger M, Kirchberger I, Steinbüchel N: Der Fragebogen Alltagsleben – ein Verfahren zur Erfassung der gesundheitsbezogenen Lebensqualität. Z Med Psychol 1993;3:121–131.
  34. Brekke JS, Raine A, Ansel M, Lencz T, Bird L: Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 1997;23:19–28.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50